Form 4: Esperion Therapeutics CEO Awarded Stock Options and Shares
SEC Form 4 Filing
Esperion Therapeutics CEO Sheldon L. Koenig received 454,000 shares of common stock and options to purchase 642,000 shares on March 14, 2024.
Summary
- On March 14, 2024, Sheldon L. Koenig, the President and CEO of Esperion Therapeutics, Inc., was granted 454,000 shares of common stock.
- Koenig also received options to purchase 642,000 shares of common stock at an exercise price of $2.05 per share.
- The stock options vest over a four-year period in equal quarterly installments, starting on June 15, 2024.
- Following these transactions, Koenig directly owns 766,816 shares of Esperion Therapeutics common stock and options to purchase 642,000 shares.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The vesting schedule is a positive sign of long-term commitment.
Positives
- The grant of stock and options to the CEO aligns his interests with those of the shareholders.
- The vesting schedule encourages long-term commitment from the CEO.
Industry Context
Stock option grants are a common practice in the pharmaceutical industry to incentivize and retain key executives.
Comparison to Industry Standards
- Executive compensation packages in the pharmaceutical industry typically include a mix of salary, bonus, stock options, and restricted stock units.
- The size and structure of the grant to Sheldon Koenig would be benchmarked against similar companies in the biopharmaceutical sector based on market capitalization, revenue, and stage of development.
Stakeholder Impact
- Shareholders may view the grant of stock options and shares as a positive sign, aligning the CEO's interests with the company's long-term success.
- Employees may see this as a positive sign of the company's commitment to its leadership.
Key Dates
| Date | Description |
|---|---|
| 03/14/2024 | Date of transaction: Grant of common stock and stock options to Sheldon L. Koenig. |
| 03/14/2034 | Expiration date of the stock options. |
| 06/15/2024 | First vesting date for the stock options. |
| 03/15/2024 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.